Increases Total Number of Board Members to Nine
MANCHESTER, NH -- (Marketwired) -- 08/06/15 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has nominated Philip Getter to its Board of Directors, effective immediately. This increases the total number of Board members to nine.
"We are excited to welcome Philip to our Board of Directors. His wealth of business experience will be a great asset as we continue to develop and grow Boston Therapeutics," said David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics.
"I am pleased to join the Board of Boston Therapeutics. BTHE is a very exciting company developing innovative solutions to significant health problems facing so many people throughout the world. I look forward to working with Dr. Platt and his team in realizing their business plan," said Mr. Getter.
Mr. Getter is President and CEO of KIDSRx International, a provider of all natural healthcare products that are made in America. Philip Getter has been the Managing Member of GEMPH Development LLC, a corporate advisory firm, since 1965. Upon graduation from Cornell University [BS-Industrial and Labor Relations] Mr. Getter served as Assistant to the Director of the United States Atomic Energy Commission. He joined Bache & Co. as a research analyst and from 1962-1969 was partner in Shearson Hammill & Co. He was Senior Partner of Devon Securities, an international corporate finance boutique from 1969-1975. Mr. Getter was a member of the New York Society of Security Analysts and wrote extensively on finance for The Market Chronicle and Phillips Media publications. Additionally, he has been guest lecturer on corporate finance at both Columbia University and Harvard Business School. He was CEO and President of Generics Corporation of America, one of the largest generic pharmaceutical companies.
As CEO and Chairman of Wolins Pharmacal Corporation, Mr. Getter led the reorganization of that direct distributor to the medical profession. In 1987, he became a financial consultant to Shearson Lehman Bros. Most recently he was Managing Director and head of Investment Banking at Prime Charter Ltd. and President of DAMG Capital. He has been a member of more than a dozen public company board of directors. He was Chairman of InkSure Technologies, Chairman of the Audit Committees of EVCI Career Colleges and ICTS International NV. He is Chairman of the Board of TCI College of Technology in NYC.
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.
Cautionary Note Regarding Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.
Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2014, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
© Boston Therapeutics, Inc. All rights reserved.
Source: Boston Therapeutics